Current Issues in Managing Group A Streptococcal Infections

  • Jonathan R. Carapetis
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 549)


Group A beta-hemolytic streptococcus (GAS, alias Streptococcus pyogenes) is a Grampositive bacterial pathogen that causes a broad spectrum of diseases as outlined in Table 25.1. This chapter will focus on some specific topics relevant to clinical management of GAS diseases.


Kawasaki Disease Sore Throat Rheumatic Fever Necrotizing Fasciitis Streptococcal Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andersson, U., Chauvet, J.M., Skansen-Saphir, U., and Andersson, J. (1994). Pooled human IgG modulates cytokine production in lymphocytes and monocytes. J. Immunol. Meth. 175, 201–213.CrossRefGoogle Scholar
  2. Basma, H., Norrby-Teglund, A., McGeer, A., Low, D.E., El-Ahmedy, O., Dale, J.B., et al. (1998). Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): Potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections. Infect. Immun. 66, 2279–2283.PubMedGoogle Scholar
  3. Carapetis, J., Walker, A., Hibble, M., Sriprakash, K., and Currie, B. (1999). Clinical and epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic superficial streptococcal infection. Epidemiol. Infect. 122, 59–65.PubMedCrossRefGoogle Scholar
  4. Cockerill, F.R., 3rd (1998). An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children [Comment]. Pediatrics, 101, 136–140.CrossRefGoogle Scholar
  5. Danchin, M.H., Curtis, N., Nolan, T.M., and Carapetis, J.R. (2002). Treatment of sore throat in light of the Cochrane verdict: Is the jury still out? Med. J. Austr. 177, 512–515.Google Scholar
  6. Darenberg, J., Ihendyane, N., Sjolin, J., Aufwerber, E., Haidl, S., Follin, P. et al., and Streptlg Study Group (2003). Intravenous immunoglobulm G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 37, 333–340.PubMedCrossRefGoogle Scholar
  7. Davies, H., McGeer, A., Schwartz, B., Green, K., Cann, D., Simor, A. et al. (1996). Invasive group A streptococcal infections in Ontario, Canada. N. Engl. J. Med. 335, 547–554.PubMedCrossRefGoogle Scholar
  8. Del Mar, C.B., Glasziou, P.P., and Spinks, A.B. (2001). Antibiotics for sore throat (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd.Google Scholar
  9. Elliott, J.A., Butler, J.C., Simon, P.A., Jameson, B.L., Welch, G.E., Facklam, R.R. et al. (1992). Streptococcus pyogenes outbreak in a long-term care facility. Clin. Infect. Dis. 15, 277–284.PubMedCrossRefGoogle Scholar
  10. Fakih, M.G., Hilu, R.C., Savoy-Moore, R.T., and Saravolatz, L.D. (2003). Do resident physicians use antibiotics appropriately in treating upper respiratory infections? A survey of 11 programs. Clin. Infect. Dis. 37, 853–856.PubMedCrossRefGoogle Scholar
  11. Gerber, M.A., Gwaltney, J.M., Jr., Kaplan, E.L., and Schwartz, R.H., Infectious Diseases Society of America, and Bisno, A. L. (2002). Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin. Infect. Dis. 35, 113–125.PubMedCrossRefGoogle Scholar
  12. Hoge, C., Schwartz, B., Talkington, D., Breiman, R., MacNeill, E., and Englender, S. (1993). The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome: A retrospective population-based study. JAMA 269, 384–389.PubMedCrossRefGoogle Scholar
  13. Kaplan, E.L. and Johnson, D.R. (2001). Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group A streptococci from children with acute pharyngitis. Pediatrics 108, 1180–1186.PubMedCrossRefGoogle Scholar
  14. Kaul, R., McGeer, A., Norrby-Teglund, A., Kotb, M., Schwartz, B., O’Rourke, K. et al. (1999). Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—a comparative observational study. The Canadian Streptococcal Study Group. Clin. Infect. Dis. 28, 800–807.PubMedCrossRefGoogle Scholar
  15. Mascini, E.M., Jansze, M., Schouls, L.M., Verhoef, J., and Van Dijk, H. (2001). Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int. J. Antimicrob. Agents 18, 395–398.PubMedCrossRefGoogle Scholar
  16. McGeer, A. and Ontario Group A Streptococcal Study Group (2003). Recommendations for investigation and chemoprophylaxis related to invasive GAS cases, including necrotizing fasciitis and streptococcal toxic shock syndrome. Ontario Group A Streptococcal Study Group, Toronto. Available at
  17. McGeer, A., Schwartz, B., Green, K., Cann, D., Simor, A.E., and Low, D.E. (1996). Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. N. Engl. J. Med. 335, 547–554.PubMedCrossRefGoogle Scholar
  18. Muller, M.P., McGeer, A., Low, D.E., and Ontario Group A Streptococcal Study (2001). Successful outcome in six patients treated conservatively for suspected neurotizing fasciitis (NF) due to group A streptococcus (GAS) [abstract]. 41st Intersci. Conf. Antimicro. Agents Chemother. Dec. 2001. Chicago.Google Scholar
  19. Norrby-Teglund, A., Kaul, R., Low, D.E., McGeer, A., Andersson, J., Andersson, U. et al. (1996a). Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect. Immun. 64, 5395–5398.PubMedGoogle Scholar
  20. Norrby-Teglund, A., Kaul, R., Low, D.E., McGeer, A., Newton, D.W., Andersson, J. et al. (1996b). Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J. Immunol. 156, 3057–3064.PubMedGoogle Scholar
  21. Norrby-Teglund, A. and Low, D.E. (2003). Group A streptococcal toxic shock syndrome and necrotizing fasciitis. Curr. Treat. Options Infect. Dis. 5, 419–429.Google Scholar
  22. Ontario Ministry of Health (1995). Guidelines for the management of contacts of cases of invasive group A streptococcal disease (GAS) including streptococcal toxic shock syndrome (STSS) and necrotizing fasciitis. Government of Canada, Ottawa.Google Scholar
  23. Prevention of Invasive Group A Streptocccal Infections Working Party (2002). Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: Recommendations from the Centers for Disease Control and Prevention. Clin. Infect. Dis. 35, 950–959.CrossRefGoogle Scholar
  24. Recco, R.A., Zaman, M.M., Cortes, H., Colucci, J., Poomkudy, G., and Kaplan, E.L. (2002). Intra-familial transmission of life-threatening group A streptococcal infection. Epidemiol. Infect. 129, 303–306.PubMedCrossRefGoogle Scholar
  25. Roy, S., Schreiber, J.R., John, C.C., Kaplan, E.L., Rodriguez, B., Salata, R.A. et al. (2003). A family cluster of five cases of group a streptococcal pneumonia. Pediatrics 112, 61–615.CrossRefGoogle Scholar
  26. Royal College of Paediatrics and Child Health (2000). RCPCH, Guidelines for Good Practice. London.Google Scholar
  27. Schwartz, B. and anonymous (1999). Nosocomial group A streptococcal infections associated with asymptomatic health-care workers—Maryland and California, 1997. Adv. Pediatr. Infect. Dis. 14, 129–145.PubMedGoogle Scholar
  28. Stevens, D.L. (2003). Dilemmas in the treatment of invasive Streptococcus pyogenes infections. Clin. Infect. Dis. 37, 341–343.PubMedCrossRefGoogle Scholar
  29. Stevens, D.L., Gibbons, A.E., Bergstrom, R., and Winn, V. (1988). The Eagle effect revisited: Efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. 158, 23–28.PubMedCrossRefGoogle Scholar
  30. Stevens, D.L., Yan, S., and Bryant, A.E. (1993). Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: An explanation for the inoculum effect. J. Infect. Dis. 167, 1401–1405.PubMedCrossRefGoogle Scholar
  31. Tanz, R.R., Poncher, J.R., Corydon, K.E., Kabat, K., Yogev, R., and Shulman, S.T. (1991). Clindamycin treatment of chronic pharyngeal carriage of group A streptococci. J. Pediatr. 119, 123–128.PubMedCrossRefGoogle Scholar
  32. Tanz, R.R., Shulman, S.T., Barthel, M.J., Willert, C., and Yogev, R. (1985). Penicillin plus rifampin eradicates pharyngeal carriage of group A streptococci. J. Pediatr. 106, 876–880.PubMedCrossRefGoogle Scholar

Copyright information

© Science+Business Media New York 2004

Authors and Affiliations

  • Jonathan R. Carapetis

There are no affiliations available

Personalised recommendations